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Background & objectives: An ideal instrument for the assessment of health related quality of life
(HRQOL) in patients with diabetes mellitus type I (T1DM) should incorporate the benefits of both
generic and disease-specific instruments. The objective of this study was to investigate the
responsiveness and the ability to provide information about diabetes-specific associations with
HRQOL, of two generic instruments, in comparison with two diabetes-specific instruments, in
patients with T1DM.
Methods: In a Dutch cohort of 234 patients with T1DM we longitudinally assessed HRQOL using
both generic and diabetes-specific instruments. We investigated the responsiveness, the
associations with diabetes-specific variables and the identification of specific patients by the
instruments used.
Results: The generic RAND-36 was able to detect statistically significant and clinically relevant
changes in HRQOL over time. Moreover, the RAND-36 was associated with (changes in) diabetes-
specific variables. The generic and diabetes-specific instruments partly identified different patients
with lowest HRQOL.
Interpretation & conclusion: The RAND-36 was highly responsive to changes in HRQOL in
patients with T1DM and revealed diabetes-specific associations with HRQOL. A low correlation
between the generic and diabetes-specific instruments and partly different identification of
patients with lower HRQOL support the complementary use of these instruments in patients
with T1DM.
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Diabetes mellitus type I (T1DM)  permanently
changes a person’s l ife.  Patient’s self  care,
consisting of daily insulin injections and self-
monitoring of blood glucose, has an impact on
health related quality of life (HRQOL). Moreover,
the acute and long-term complications which might
develop will also affect a person’s HRQOL1. Many
different instruments have been developed to
measure the physical, psychological and social
aspects of HRQOL2-6. One can distinguish between
generic and disease-specific HRQOL instruments7,8.
Generic instruments are applicable to healthy people
as well as to persons with diseases, and thereby
enable comparisons to be made between various
groups of patients and general population samples.
Moreover, the general public has valued different
health states,  provided by some generic
questionnaires, which makes economic evaluations
possible9-11. Disease-specific instruments focus on
a population with a specific disease and are expected
to be more sensitive to treatment effects and changes
over time than generic instruments7,8. The limitation
of these instruments, however, is that the scores
such instruments generate remain specific for the
affliction studied. Many cross-sectional studies,
using different instruments of both types have
shown that in TIDM older and female patients,
patients without a partner, patient with a lower
education, and patients with complications are at
risk for a decrease in HRQOL12-28.
An ideal instrument for the assessment of
HRQOL in T1DM should incorporate the benefits of
both generic and diabetes-specific instruments. It
should be sensitive for changes, provide information
about diabetes-specific associations with HRQOL,
enable comparisons between various groups of
patients or general population samples and make
economic evaluations possible.
The aim of this study was to investigate these
properties of two generic instruments in the
assessment of HRQOL in T1DM. In addition, the
feasibility of these instruments and the clinical
relevance of their results were also investigated.
We therefore examined whether the generic
instruments used in our study are capable of
measuring (clinically relevant) changes in HRQOL
in patients with T1DM and whether these generic
instruments can identify diabetes-specific
associations with HRQOL. An additional aim was to
examine whether diabetes-specific and generic
instruments identify the same patients, when low
HRQOL scores are assessed.
Material &  Methods
Patients: In 1995 a total of 293 consecutive T1DM
patients seen at the outpatient clinic of the Isala
Clinics in Zwolle, the Netherlands, were invited to
participate in the study. Of these, 281 patients agreed
and were investigated from 1995 onwards on a yearly
basis. T1DM was defined as starting insulin therapy
within six months after the first signs of diabetes
mellitus and before the age of 30 yr, or the absence
of C-peptide secretion. Ethics committee approval
was obtained from the Hospital Scientific and Ethics
Committee. Informed consent was obtained from all
patients.
Health related quality of life (HRQOL) : Two
different, frequently applied generic instruments, the
RAND-36 and the EuroQol, which have both been
translated and validated for the Dutch situation were
used. In addition, two different diabetes-specific
instruments (Problem Areas In Diabetes, Fear of
Hypoglycamia Scale) were used to measure some
diabetes-specific aspects of HRQOL and to make
comparisons possible with the generic
assessments9,29-31.
These four instruments were sent to the patient’s
home address in one package. Patients were asked
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to fill in the questionnaires at home. At the next visit
to the outpatient clinic the patients returned the
completed questionnaires to the diabetes specialist
nurse. Patients who did not return the completed
questionnaires when visiting the clinic were asked
to send their completed questionnaires afterwards.
The RAND-36 is a self-administered, generic
questionnaire containing 36 items involving eight
different subscales. For each subscale, scores are
transformed to a scale from 0 (worst health) to 100
(best health)30,32. In addition, physical and mental
component summary scores can be determined (PCS/
MCS)33. The questionnaire takes about ten minutes
to complete. The instrument has been translated into
Dutch34 and validated for the Dutch population35. The
RAND-36 was assessed yearly.
The Euroqol (EQ): The EuroQol was developed by a
multidisciplinary group of researchers from five
European countries to describe and value health
states9. It is a generic, multidimensional measure,
consisting of two parts, and takes about 2 min to
complete by the patient.
The first part consists of five questions covering
5 dimensions (EQ-5D). Each dimension is divided
into 3 levels: ‘no problem’, ‘some/ moderate
problems’ and ‘extreme/ unable to’. A respondent’s
health state is defined by combining one level from
each of the 5 dimensions. A total of 243 possible
health states can be defined in this way. Valuations
of these health states have been made, by the U.K.
general public, using time trade-off36. The set of
possible values has a range of -0.594 to 1, where 1 is
the value of perfect health, 0 is the value of death
and –0.594 indicates the worst possible health state,
which is viewed by the general public as considerably
worse than death.
The second part, a single overall score, can be
gained from a “thermometer”: a self-rated health
status using a graduated (0-100) visual analogue scale
(EQ-VAS), in which 0 indicates worst HRQOL and
100 best possible HRQOL. The EuroQol has been
validated for the Dutch situation37. The EQ was
assessed in 1995 through 1998, and in 2001.
The problem areas in diabetes survey (PAID): The
PAID was developed as a new measure of
psychosocial adjustment to diabetes. It is a diabetes-
specific, unidimensional instrument. The instrument
can be scored quickly, in 3-5 min, by the patient. Its
primary aim is to tap the breadth of emotional
responses to diabetes31,38. The PAID is a 20-item
questionnaire in which each item represents a unique
area of diabetes-related psychosocial distress. The
items are divided over four areas. A total score,
hypothesised to reflect the overall level of diabetes-
related emotional distress, is computed by summing
the 20 item responses. It is scored on a scale of 0 to
100, with higher PAID scores indicating greater
emotional distress. Reliability and validity are
good31,38 and the PAID has been validated for the
Dutch situation39. The PAID was assessed in 1998
and 2001.
The fear of hypoglycaemia scale (FHS): The FHS
was developed as a research and clinical tool
measuring the degree of fear experienced with respect
to hypoglycaemia29. Worries about hypoglycaemia
as well as behaviour designed to avoid
hypoglycaemia are examined. It is a diabetes-
specific, unidimensional measure. The scale consists
of 23 items: 13 items concerning worry and fear and
10 items concerning behaviour or avoidance. The 13
worry items can be summed to a Worry subscale,
while the 10 behaviour items can be summed to a
Behaviour subscale. Together, the two subscales can
be summed to create the total FHS-score, a higher
score indicating greater fear for hypoglycaemia40.
Various studies support the validity and the reliability
of the FHS29,40. We only used the Worry subscale,
since at the time of the study the validity of the
behaviour subscale was discussed40,41. The Worry
subscale was assessed in 1997 and 2001.
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Clinical data: Socio-demographic data including sex,
age, marital status and level of education were
recorded. Therapy-specific data were recorded and
included pen-/ pump use, frequency of insulin
injections and number of blood glucose control
measurements per week. Metabolic control was
assessed by measuring glycosylated haemoglobin
A1c (HbA1c). The acute complications of the therapy
were also recorded; patients recorded all
hypoglycaemic events during the three months
preceding the outpatient visit. Patients were asked
to report whether they had one or more of six different
hyperglycaemic complaints during the previous three
months (yes/ no): tiredness, weight loss, pruritus,
thirst, polyuria and polydipsia.
Using a list of 26 chronic diseases/ diagnoses the
patients could indicate which other diseases they had
besides diabetes42. When they indicated one or more
chronic diseases, apart from diabetes mellitus, they
were scored as having comorbidity.
Chronic complications
Microvascular complications-Patients with
retinopathy, neuropathy or nephropathy were
categorised as having microvascular complications.
Retinopathy-The ophthalmologist examined all
patients annually. The degree of diabetic retinopathy
was assessed by fundoscopy in mydriasis. The
classification of diabetic retinopathy used was based
on de Jong43: no retinopathy (=0), background
retinopathy (=I), preproliferative (=II) and
proliferative diabetic retinopathy (=III). Retinopathy
was scored positive when any type of retinopathy
was present in either eye. When the degree of
retinopathy was different in two eyes, the highest
degree was scored.
Neuropathy-Sensitivity was tested by the
Semmes-Weinstein pressure aesthesiometer44. At five
dorsal and plantar sites on the foot (left and right)
sensibility was tested with six different
monofilaments. When the monofilament 5.07 was not
felt at one of the ten test sites, patients were
considered to have neuropathy.
Nephropathy-The 24 h urinary excretion of
albumin (UAER) was measured annually. UAER was
considered abnormal when it was >30 mg/24 h.
Micro-albuminuria was defined as 30-300 mg/ 24 h
and macro-albuminuria as >300 mg/24 h. All patients
with micro-albuminuria or macro-albuminuria were
defined as having nephropathy45-47. At the Isala
clinics, patients with micro-albuminuria
>100 mg/24 h received an angiotensin converting
enzyme inhibitor (ACE-inhibitor) in 1995. We
included ace-inhibitor users, even with
normalbuminuria, as having nephropathy, when
treatment was initiated for micro-albuminuria at an
earlier stage.
Macrovascular complications-The clinician
recorded the status of macrovascular complications.
Patients were classified as having macrovascular
complications when one or more of the following
diagnoses was present: angina pectoris, myocardial
infarction, intermittent claudication, transient
ischaemic attack (TIA), or a cerebrovascular accident
(CVA).
Statistical analysis-Responsiveness of the
RAND-36 and the EuroQol was investigated in
patients with T1DM, to answer the question whether
these generic instruments are sensitive for changes
in HRQOL. Although responsiveness is considered
to be an essential property of an evaluative
instrument, the methodology of assessing
reponsiveness tends to be less well understood48.
In this study three methods were applied to
investigate responsiveness of the generic instruments
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used in our cohort. Firstly, we investigated the ability
to detect, longitudinally, statistically significant
changes in HRQOL over time (1998-2001) using
paired sample T-tests. Since the diabetes-specific
instruments were assessed only in 1998 and 2001,
we used this time interval.
Secondly, we investigated whether the observed
changes were also clinically relevant. The developers
of the RAND-36 and the EuroQol do not provide cut-
off points for clinically important changes in HRQOL
scores. However, changes of >2-5 points for the
RAND-subscales and >1 point for the RAND
summary scores are sometimes considered as the
smallest clinically significant changes32,49,50. For the
EQ-5D and the EQ-VAS, 0.05 points and five points
can be used as a rough guide although formally the
EuroQol Group has not published any minimally
significant values.
Finally, we investigated whether the generic
instruments assessed changes in HRQOL when
changes were expected on the basis of changes in
diabetes-specific clinical characteristics. We
Table I. Personal and disease-specific characteristics of the study population (n=234)
1995 1998 2001
Gender (men) 134 (57.3%) 134 (57.3%) 134 (57.3%)
Age (yr) 38.2 11.5) 41.2 (11.5) 44.2 (11.5)
Duration of diabetes (yr) 16.5 (10.1) 19.5 (10.1) 22.5 (10.1)
Married/ cohabiting 207 (90.8%) 194 (89.4%) 189 (87.9%)
High level of education 76 (33.6%) 72 (34.0%) 76 (35.5%)
Systolic blood pressure (mm Hg) 138.9 (17.8) 131.1 (19.4) 131.5 (19.2)
Diastolic blood pressure (mm Hg) 83.0 (8.4) 79.4 (10.2) 77.8 (10.4)
Body mass index (kg/m2) 24.8 (3.2) 25.6 (3.6) 26.1 (4.0)
HbA1c (%) 8.1 (1.9) 7.9 (1.3) 7.6 (1.1)
Insulin pump 63 (26.9%) 76 (32.6%) 102 (43.6%)
Insulin pen 171 (73.1%) 157 (67.4%) 132 (56.4%)
Frequency of insulin pen
injections (per day)
1-3 24 (14.0%) 22 (14.0%) 19 (14.4%)
4 147 (86.0%) 128 (81.5%) 108 (81.8%)
>4 0 (0.0%) 7 (4.5%) 5 (3.8%)
No. of control measurements (per wk) 12.0 (11.3) 18.2 (14.4) 20.0 (15.2)
Patients with:
Hypoglycaemic events last 3 months 185 (80.8%) 180 (84.9%) 173 (87.4%)
Hyperglycaemic complaints last 3 months 122 (53.3%) 105 (50.5%) 116 (58.3%)
Comorbidity (at least one 133 (58.1%) 130 (62.5%) 107 (52.7%)
comorbid condition)
Patients with diabetic complications
Microvascular 104 (45.8%) 111 (58.1%) 119 (65.7%)
Retinopathy 79 (34.6%) 88 (44.9%) 99 (48.5%)
Nephropathy 43 (18.4%) 33 (16.7%) 45 (23.0%)
Neuropathy 24 (10.4%) 32 (15.2%) 23 (12.2%)
Macrovascular 10 (4.3%) -     - 23 ( 9.8%)
Values are number of patients (with valid percentages between parentheses) or means (with standard deviation between parentheses)
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expected a decrease in HRQOL for the patients who
developed microvascular complications between
1998 and 2001 and compared the means of the
patients who developed microvascular
complications and of the patients who did not (using
the Mann Whitney test).
To investigate whether the generic instruments
can provide information about diabetes-specific
influences on HRQOL, we did multivariate stepwise
regression analyses to investigate cross-sectional
associations of HRQOL scores with several
demographic and disease-specific patient
characteristics (in 2001). The different HRQOL
scales were the dependent variables and all the
personal and disease specific variables (Table I)
were the independent variables. We used the
adjusted R 2 (result of the multivariate regression
analysis)  to describe the degree of variance in
HRQOL explained by the model.
To investigate whether diabetes-specific and
generic instruments identify the same patients, we
calculated correlations between the different
instruments using Spearman rank correlation
coefficients. Moreover, for each instrument the
10 per cent lowest and 10 per cent highest scores
(in 2001) were defined and the patients, thus
identified by the different instruments, were
compared. Finally, we described several feasibility
characteristics of the instruments, to provide
practical information for the use of these
instruments.
Relationships were considered statistically
significant with P<0.05. Data were analysed using
SPSS for Windows, version 10.0.
Results
A total of 281 adult patients with type I diabetes
mellitus entered the study in 1995.
The dropout rate over these six years was 16.7
per cent (n=47). Dropouts were more frequently
women (59.6 vs. 42.7%, P=0.04), more often single
(24 vs. 9.2%, P=0.01), had a longer disease-duration
(20.6 vs.16.5 yr, P=0.05), and a higher HbA1c (9.0
vs. 8.1, P=0.007) and reported a lower baseline
HRQOL.
Personal and disease-specific characteristics of
the patients who completed the study period of six
years are shown in Table I (n=234). Data are shown
for the years 1995, 1998 and 2001. Mean age at entry
Table II. Health related quality of life in 1998 versus 2001
1998 2001 P value
RAND-36:
Physical functioning 91.0 (15.8) 87.3 (19.0) 0.004
Role physical 81.2 (33.3) 76.2 (37.8) 0.070
Bodily pain 87.5 (19.9) 83.6 (20.2) 0.016
General health 66.8 (18.9) 64.4 (20.3) 0.015
Vitality 68.3 (19.8) 61.6 (20.0) <0.001
Social functioning 86.5 (18.6) 84.2 (20.3) 0.086
Role emotional 83.0 (35.5) 83.5 (32.6) 0.913
Mental health 79.9 (15.9) 77.1 (16.1) 0.004
Physical summary 51.5 (7.6) 49.8 (9.1) 0.006
score
Mental summary 51.7 (9.5) 50.9 (9.3) 0.176
score
EuroQol:
EQ-5D 0.87 (0.18) 0.85 (0.19) 0.191
EQ-VAS 77.1 (14.4) 76.0 (13.5) 0.054
PAID:
Diabetes related 13.8 (11.8) 14.9 (12.0) 0.073
Treatment related 1.7 (2.7) 2.2 (2.9) 0.030
Food related 2.5 (2.7) 2.4 (2.6) 0.862
Social support 1.1 (1.9) 1.1 (1.8) 0.808
related
Total score 19.5 (17.2) 20.5 (17.5) 0.254
Hypoglycaemia fear:
Worry subscale 10.9 (8.4)* 10.7 (8.0) 1.000
Values are means with standard deviations between parentheses
P values are based on paired sample T-Tests
HRQOL data in this table are based on 213-220 patients,
resulting in 204-213 paired samples
Worry subscale was assessed in 1997
EQ-5D, EuroQol utility index; EQ-VAS, EuroQol Visual
Analogue Scale; PAID, Problem Areas in Diabetes
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was 38.2 yr, and 57.3 per cent were men. The
percentage of patients using a pump increased from
26.9 per cent in 1995 to 32.6 per cent in 1998
(P=0.002) to 43.6 per cent in 2001 (P<0.001). The
therapy was intensified over the six-year study
period. An increased number of control
measurements per week, a lower HbA1c and rise in
body mass index were observed over this period. The
percentage patients with hypoglycaemic events did
not increase significantly between 1995 and 2001.
The percentage of patients with microvascular
complications increased from 45.8 per cent in 1995
to 58.1 per cent in 1998 (P=0.005) and later to 65.7
per cent in 2001 (P=0.248). In 1995 the percentage
of patients with macrovascular complications was 4.3
per cent and in 2001 9.8 per cent (P<0.001).
Ability to detect change in HRQOL over time:
RAND-36. Five subscales of the RAND-36 and the
PCS showed a statistically significant decrease in
HRQOL over time. The subscales role physical and
social functioning and the mental component
summary tended to decrease, whereas the subscale
role emotional remained stable between 1998 and
2001. Seven RAND-subscales and the PCS showed
a clinically relevant change over time within this
study period. The subscale role emotional and the
MCS did not show a clinically relevant change in
HRQOL over time (Table II).
EuroQoL: The EQ-5D as well as the EQ-VAS tended
to decline between 1998 and 2001. This decline was
not statistically significant and/ or clinically relevant.
In both years the percentage of patients with the
highest possible EQ-5D score was high (52.3 and
46.6% respectively).
PAID: The problems related to treatment increased
after 3 yr follow up (P=0.03). The diabetes related
problems and the total score tended to increase,
whereas the problems related to food and social
support remained stable over time.
Hypoglycaemia fear: The degree of worry was not
increased after the 3 yr period (Table II).
Ability to detect real changes in the concept being
measured:  The patients, who developed
microvascular complication(s) between 1998 and
2001 reported a faster decrease in MCS and EQ-5D
than the patients without new microvascular
complication(s) [MCS -4.85 vs+0.26, P=0.006 and
EQ-5D -0.09 vs. +0.02, P=0.013)].
Table III.  Results of the multivariate regression analysis of health related quality of life scores in 2001
PCS MCS EQ-5D EQ-VAS PAID-total Worry
subscale
R2 0.243 0.075 0.180 0.157 0.083 0.038
(n=180) (n=192) (n=177) (n=177) (n=184) (n=201)
Intercept 55.4 54.6 0.96 82.9 14.4 19.77
HbA1c -1.29
(P=0.014)
Hyperglycaemia - 4.71 -5.03 -0.09 -6.80 10.85
(P<0.001) (P<0.001) (P<0.001) (P<0.001) (P<0.001)
Co-morbidity - 2.78 -0.05
(P=0.018) (P=0.033)
Macrovascular -10.03 -0.135 -11.6
complications (P<0.001) (P=0.002) (P=0.001)
R2, Adjusted R square; Intercept, mean value of the population; PCS, physical component summary; MCS, mental component summary;
EQ-5D, EuroQol utility index; EQ-VAS, EuroQol Visual Analogue Scale; PAID, problem areas in diabetes
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Ability to provide information about diabetes-
specific associations with HRQOL: Table III shows
the results of the multivariate stepwise regression
analyses. The explained variance in HRQOL varied
from 3.8 (Worry scale) to 24.3 per cent (PCS).
Only four characteristics showed a statistically
significant association with a HRQOL scale; the
presence of hyperglycaemic complaints,  co-
morbidity and macrovascular complications were
all negatively associated with HRQOL. A lower
HbA1c was associated with more worries about
hypoglycaemia (P=0.014).  Both generic
instruments revealed a negative associat ion
between the presence of comorbidity and HRQOL
(PCS and EQ-5D).
The presence of macrovascular complications
had the most pronounced negative association with
HRQOL; these patients reported a lower PCS, EQ-
5D, EQ-VAS. Patients with hyperglycaemic
complaints also had a lower HRQOL (PCS, MCS,
EQ-5D, EQ-VAS) and reported more diabetes related
emotional distress (PAID).
Identification of specific patients: Table IV shows
the Spearman rank order correlations between the
different instruments.
Generic/generic  -  the PCS showed a s trong
correlat ion with the EQ-5D and a moderate
correlation with the EQ-VAS. The MCS was
Table IV. Spearman rank order correlations between the different quality of life scales





EQ-5D 0.643  0.409 -
(P<0.001) (P<0.001)
EQ-VAS  0.531  0.557  0.613 -
(P<0.001) (P<0.001) (P<0.001)
PAID -0.263 -0.457 -0.293 -0.432 -
(P<0.001) (P<0.001) (P<0.001) (P<0.001)
Worry subscale -0.219 -0.402 -0.281 -0.296 0.627 -
(P=0.002) (P<0.001) (P<0.001) (P<0.001) (P<0.001)
PCS, physical component summary; MCS, mental component summary; EQ-5D, EuroQol utility index ; EQ-VAS,  EuroQol Visual
Analogue Scale; PAID, problem areas in diabetes
Table V. Percentage of patients with 10 per cent lowest HRQOL identified by both instruments
PCS MCS EQ-5D EQ-VAS PAID Worry
subscale
PCS - 9.5 50.0 60.0 19.1 20.0
MCS   9.5 - 33.3 38.9 42.1 30.0
EQ-5D 58.8 29.4 - 72.2 23.5 25.0
EQ-VAS 41.4 24.1 46.4 - 26.7 21.4
PAID 21.1 42.1 33.3 47.1 - 55.6
Worry subscale 17.4 26.1 21.1 28.6 43.5 -
PCS, physical component summary; MCS. mental component summary; EQ-5D, EuroQol utility index; EQ-VAS, EuroQol Visual
Analogue Scale; PAID, Problem Areas in Diabetes
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moderately correlated with the EuroQol scales. The
PCS and MCS were not correlated, inherent to the
method we chose to calculate  the summary
scores33.
Diabetes-specific/diabetes-specific - the PAID was
strongly correlated with the Worry subscale.
Generic/diabetes-specific - The PCS and EQ-5D
correlated only weakly with the more psychological
health scales (i.e., the PAID and the Worry subscale),
whereas the MCS and EQ-VAS correlated moderately
with the PAID and the Worry scale (MCS).
Table V shows the extent to which the
instruments identified the same patients within the
10 per cent lowest HRQOL range. The percentage of
agreement was highest between the PCS, the EQ-5D
and EQ-VAS. For example, of the patients with the
10 per cent lowest PCS scores, 60 per cent reported
lowest EQ-VAS scores. Of the patients with the
highest hypoglycaemia worry scores, only a quarter
was found in the lowest MCS-score category
(26.1%). Patients reporting most diabetes-related
emotional distress had in 42.1 per cent lowest MCS
scores.
Table VI shows that of the patients with the
10 per cent highest Worry and PAID scores, here
defined as having the least worries about
hypoglycaemia and problems about diabetes, only
15.8 and 26.7 per cent of the patients, respectively
had highest MCS scores.
Feasibility: Table VII shows several feasibility data of
the instruments used in our cohort. All four instruments
led to very high percentages of valid scores.
Discussion
In our study we followed a Dutch cohort of 234
patients with T1DM for three years. We used both
generic and diabetes-specific HRQOL instruments
to assess HRQOL.
Table VI. Percentage of patients with 10 per cent highest QOL identified by both instruments
PCS MCS EQ-5D EQ-VAS PAID Worry
subscale
PCS - 9.1 63.6 25.0 30.0 18.2
MCS   9.5 - 47.6 38.0 40.0 15.0
EQ-5D 14.6 10.4 - 15.6 17.4 12.8
EQ-VAS 25.0 40.0 75.0 - 42.1 35.0
PAID 20.0 26.7 53.3 27.6 - 31.0
Worry subscale 21.1 15.8 66.7 35.0 56.3 -
PCS, physical component summary; MCS, mental component summary; EQ-5D, EuroQol utility index; EQ-VAS, EuroQol Visual
Analogue Scale; PAID, problem areas in diabetes
Table VII. Several feasibility data of the different instruments used in the cohort
No. of No. of Total Completion Suitable for self- Valid scores
subscales  items score time in min assessment (1998)
RAND-36 8 36 Yes 10 Yes 92.3-93.6%
EuroQol 5 6 Yes 2 Yes 93.2-93.6%
PAID 4 20 Yes 3-5 Yes 89.7-92.7%
HFS 2 23 Yes 3 Yes 92.7%*
PAID, problem areas in diabetes; HFS, hypoglycaemic fear survey; *based on worry subscale
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A central question was how well the generic
RAND-36 and EuroQol capture changes in HRQOL
in patients with T1DM and whether they provide
information about diabetes-specific associations with
HRQOL. Moreover we examined the feasibility and
the clinical relevance of their results. Could these
generic instruments replace the diabetes-specific
instruments in the assessment of HRQOL in T1DM?
The responsiveness of the generic RAND-36 was
good: it was sensitive to changes in HRQOL over
three years and the changes could also be considered
clinically relevant. Moreover, the RAND mental
summary score (MCS) was associated with a change
in a diabetes-specific characteristic. The onset of
microvascular complications was associated with a
decrease in MCS, which we can explain by the fact
that the knowledge of having a microvascular
complication will negatively influence mental health.
Very likely the PCS will be influenced negatively
later, when the severity of the microvascular
complications is increased, and the complications
become symptomatic. These symptoms will
influence patient’s functioning and thereby HRQOL
indirectly51.
The responsiveness of the EQ was limited. The
mean observed changes in EQ between 1998 and
2001 were neither statistically significant nor
clinically relevant. Moreover, this instrument showed
a considerable ceiling effect, in that half of the
patients reported the best possible HRQOL. This
inability of the EQ to differentiate between small
differences in the highest HRQOL ranges has
previously been described52,53. Nevertheless, the EQ-
5D decreased when microvascular complications
developed.
Patients reported more treatment related
problems in 2001 than in 1998. Earlier studies
provided support for the responsiveness for changes
of the PAID54. Indeed therapy was intensified during
that period. No associations were found between
PAID scores and objective factors of intensified
therapy (i.e., pump use/ more than 4 times daily pen
injection, higher frequency of self monitoring blood
glucose, lower HbA1c) or the possible side effects
of an intensified therapy (weight gain and more
hypoglycaemic events) and PAID scores. The PAID
scores purely reflected patient’s subjective self-report
and evaluation of problems concerning treatment.
The Worry subscale did not show changes over time.
Although the HbA1c declined significantly, the
number of patients that reported hypoglycaemic
events did not increase significantly, which might
explain this result.
We therefore conclude that the generic RAND-
36 was highly responsive to changes in HRQOL over
time and to changes in a diabetes-specific variable.
Both the RAND-36 and the EuroQol provided
information about diabetes-specific influences on
HRQOL. Hyperglycaemia and the presence of
macrovascular complications were associated with
a lower HRQOL. The generic instruments showed a
lowered HRQOL in the presence of non-diabetic
morbidity (co-morbidity), whereas the diabetes-
specific instruments did not. Woodcock et al55
reported in a general practice T2DM population the
negative influence of co-morbidity on generic
measured HRQOL and used this finding to support
the complementary use of generic and disease-
specific instruments.
Although the PCS is a generic measure, the model
used to explain variance in PCS resulted in the largest
percentage explained variance (i.e., 24.3%). This
percentage was much lower for the MCS, the
EuroQol, the Worry subscale of the HFS and the
PAID. This suggests that it is easier to explain
variance in the more physical aspects than in the more
mental aspects of HRQOL. The RAND-36 is
multidimensional and approaches HRQOL as broadly
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as possible, including physical, psychological and
social aspects. In contrast, the HFS worry scale and
the PAID are uni-dimensional and focus on a small
though important portion of the concept HRQOL of
patients with T1DM56.
We can state that the generic RAND-36, and the
EQ in a less degree, gave information about diabetes-
specific influences on HRQOL. This information was
partly different from that provided by the diabetes-
specific, uni-dimensional instruments used in our
study2,4,38,56,57.
The low correlations between the generic and
diabetes-specific instruments used in our study
suggest that these instruments measure different
aspects of health. Indeed, rather different aspects,
ranging from problems with one’s job (‘did you have
any problem with your work as result of your physical
health?’ RAND-36) to fear for hypoglycaemia (‘do
you worry about passing out in public?’ HFS) are
assessed2. When instruments have a low correlation,
a complementary use of these instruments can give
additional information.
The generic and diabetes-specific instruments in
our study only partly identified the same patients with
the lowest or highest HRQOL. When a clinician
wishes to identify and select patients who are at
greatest risk of a worsening in HRQOL, the choice
of the instrument will influence which patients will
be identified. For example, for patients showing poor
glycaemic control, a clinician can wonder whether
these patients are more afraid of hypoglycaemic
events than others, since this fear can lead to non-
compliance and poor glycaemic control. This specific
question should lead to a carefully considered choice
of instrument, and in this case, the HFS would be
the most appropriate choice.
Although the RAND-36 questionnaire consists
of more items and takes longer to complete than other
instruments, this did not lead to a lower response rate
or a lower percentage of valid scores. Apparently,
the length of this instrument and the longer
completion time were not a problem in this group of
patients.
In conclusion, the generic RAND-36 appears
to be very sensitive to changes in HRQOL in a
cohort of patients with T1DM. Although the
RAND-36 is a generic instrument, it provides
information about diabetes-specific associations
with HRQOL. The generic and diabetes-specific
instruments show low correlations and identify for
the most part different patients with the lowest
HRQOL. We recommend the use of the RAND-36
for assessing HRQOL in patients with T1DM. The
complementary use of a diabetes-specific measure
like the PAID and the HFS will give additional
information about the psychological status of
patients with T1DM.
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